Ashley L. Cook

Ashley L. Cook

Auto-generated profile, based on publicly available information

Ashley L. Cook

Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2022 in Nature
Verified
Journal Article
Open access
PDF file
DEDaniel J. Emerson
Daniel J. Emerson
PZPeiyao A. Zhao
Peiyao A. Zhao
ACAshley L. Cook
Ashley L. Cook
RBR. Jordan Barnett
R. Jordan Barnett
KKKyle N. Klein
Kyle N. Klein
JPJennifer E. Phillips-Cremins
Jennifer E. Phillips-Cremins
DNA replication occurs through an intricately regulated series of molecular events and is fundamental for genome stability1,2. At present, it is unknown how the locations of replication origins are determined in the human genome. Here we dissect the role of topologically associating domains (TADs)3–6, subTADs7 and loops8 in the positioning of replication initiation zones (IZs). We stratify TADs and subTADs by the presence of corner-dots indicative of loops and the orientation of CTCF motifs. We find that high-efficiency, early replicating IZs localize to boundaries between adjacent corner-dot TADs anchored by high-density arrays of divergently and convergently oriented CTCF motifs. By contrast, low-efficiency IZs localize to weaker dotless boundaries. Following ablation of cohesin-mediated loop extrusion during G1, high-efficiency IZs become diffuse and delocalized at boundaries with complex CTCF motif orientations. Moreover, G1 knockdown of the cohesin unloading factor WAPL results in gained long-range loops and narrowed localization of IZs at the same boundaries. Finally, targeted deletion or insertion of specific boundaries causes local replication timing shifts consistent with IZ loss or gain, respectively. Our data support a model in which cohesin-mediated loop extrusion and stalling at a subset of genetically encoded TAD and subTAD boundaries is an essential determinant of the locations of replication origins in human S phase.

23 May 2022 in iScience
Verified
Journal Article
Open access
ACAshley L. Cook
Ashley L. Cook
NWNicolas Wyhs
Nicolas Wyhs
SSSurojit Sur
Surojit Sur
BPBlair Ptak
Blair Ptak
MPMaria Popoli
Maria Popoli
KKKenneth W. Kinzler
Kenneth W. Kinzler
We describe the creation of an isogenic cell line panel representing common cancer pathways, with features optimized for high-throughput screening. More than 1,800 cell lines from three normal human cell lines were generated using CRISPR technologies. Surprisingly, most of these lines did not result in complete gene inactivation despite integration of sgRNA at the desired genomic site. A subset of the lines harbored biallelic disruptions of the targeted tumor suppressor gene, yielding a final panel of 100 well-characterized lines covering 19 frequently lost cancer pathways. This panel included genetic markers optimized for sequence-based ratiometric assays for drug-based screening assays. To illustrate the potential utility of this panel, we developed a high-throughput screen that identified Wee1 inhibitor MK-1775 as a selective growth inhibitor of cells with inactivation of TP53. These cell lines and screening approach should prove useful for researchers studying a variety of cellular and biochemical phenomena.

29 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAshley L Cook
Ashley L Cook
SSSurojit Sur
Surojit Sur
LDLaura Dobbyn
Laura Dobbyn
EWEvangeline Watson
Evangeline Watson
JCJoshua D Cohen
Joshua D Cohen
NWNicolas Wyhs
Nicolas Wyhs
Summary: Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from truncating mutations in vivo and in vitro . Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable HLA class I-associated peptides from NMD-downregulated proteins on the surface of cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases. One Sentence Summary: Disruption of the nonsense-mediated decay pathway with a newly developed SMG1 inhibitor with in-vivo activity increases the expression of T-cell targetable cancer neoantigens resulting from truncating mutations.

1 April 2025 in The CRISPR Journal
Verified
Journal Article
Closed access
ACAshley L. Cook
Ashley L. Cook
AMAdam L. Moyer
Adam L. Moyer
LBLynne Boxer
Lynne Boxer
ANAlexis Norris
Alexis Norris

17 February 2025 in eLife
Verified
Journal Article
Open access
ACAshley L Cook
Ashley L Cook
SSSurojit Sur
Surojit Sur
LDLaura Dobbyn
Laura Dobbyn
EWEvangeline Watson
Evangeline Watson
JCJoshua D Cohen
Joshua D Cohen
NWNicolas Wyhs
Nicolas Wyhs
Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.

29 July 2024 in eLife preprints
Verified
Preprint
Open access
ACAshley L Cook
Ashley L Cook
SSSurojit Sur
Surojit Sur
LDLaura Dobbyn
Laura Dobbyn
EWEvangeline Watson
Evangeline Watson
JCJoshua D Cohen
Joshua D Cohen
NWNicolas Wyhs
Nicolas Wyhs
Summary Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from truncating mutations in vivo and in vitro. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable HLA class I-associated peptides from NMD-downregulated proteins on the surface of cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.